Lindsey Schutte, PA
Physician Assistant · Dakota Dunes, SDNPI 1588164107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 35.7% of the total. Among physician assistant clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$862
- Amgen$224
- Novo Nordisk$223
- Astellas Pharma US Inc$216
- Pfizer$185
- AstraZeneca$72
- plus $633 from 20 others
What the payments were for
- Food & beverage$2,31496%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $862 |
| Amgen | 14 | $224 |
| Novo Nordisk | 14 | $223 |
| Astellas Pharma US Inc | 9 | $216 |
| Pfizer | 12 | $185 |
| AstraZeneca | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 5 | $62 |
| Bayer | 3 | $61 |
| Merck | 3 | $52 |
| Lilly USA, LLC | 4 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $47 |
| Boehringer Ingelheim | 2 | $45 |
| Amarin Pharma, Inc. | 3 | $43 |
| Biogen | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Grifols USA, LLC | 1 | $26 |
| GSK | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Medtronic | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
How this compares
$2,414 in reported general payments places this provider in the 90th percentile of 548 physician assistant providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $31,389 |
| MounjaroTirzepatide | 20 | $22,545 |
| XareltoRivaroxaban | 19 | $21,941 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $20,370 |
| EliquisApixaban | 17 | $18,335 |
| FarxigaDapagliflozin Propanediol | 15 | $8,407 |
| VeozahFezolinetant | 14 | $6,492 |
| Novolog FlexpenInsulin Aspart | 11 | $3,923 |
| SynthroidLevothyroxine Sodium | 43 | $1,751 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,644 |
| Bupropion XlBupropion Hcl | 58 | $1,410 |
| Levothyroxine Sodium | 187 | $1,281 |
| Ventolin HfaAlbuterol Sulfate | 18 | $961 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $872 |
| Atorvastatin Calcium | 136 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $26 | $51,75976 claims |
| Lilly USA, LLCMounjaro | $51 | $22,54520 claims |
| Johnson & JohnsonXarelto | $16 | $21,94119 claims |
| PfizerEliquis | $185 | $18,33517 claims |
| AstraZenecaFarxiga | $72 | $8,40715 claims |
| Astellas Pharma US IncVeozah | $216 | $6,49214 claims |
| AbbVieSynthroid | $862 | $1,75143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 548 physician assistant providers in South Dakota.
Other physician assistant in Dakota Dunes
- Alyssa MrsnyDakota Dunes$7K
- Stephanie FeltsDakota Dunes$6K
- Emily KruseDakota Dunes$5K
- Amy DietrichDakota Dunes$4K
- Lukas SachauDakota Dunes$3K
- Daniel MooreDakota Dunes$2K
- Kimberly NelsonSioux Falls$11K
- Jordan HeinsRapid City$10K
- Ryanne WaageAberdeen$9K
- Christina PekoskeSioux Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.